In the Matter of Baxter International, a corporation

File No. 971 0002

Docket No. C-3726

July 29, 2003

  • Letter to Daniel Tripodi, Ph.D., Approving Request to Extend Through July 28, 2004, the Period During Which Haemacure Corporation May Continue to Seek to Obtain Certain Food and Drug Administration Approvals to Manufacture Fibrin Sealant For Sale in the United States
  • News Release

May 9, 2003

  • Letter Approving Request to Extend Through May 8, 2004, the Period During Which NABI May Continue to Seek to Obtain Certain Food and Drug Administration Approvals of Its Own to Manufacture Baxter's Factor VIII Inhibitor Treatments. [PDF 86K]
    • Letter to Daniel Tripodi, Ph.D.
  • News Release

June 28, 2002

  • Letter Approving Request to Extend Through July 28, 2003, the Period During Which Haemacure Corporation May Continue to Seek Certain Food and Drug Administration Approvals.[PDF 30KB]
  • News Release

May 7, 2002

  • Letter Approving Request to Extend Through May 8, 2003, the Period During Which NABI may Continue to Seek Certain Food and Drug Administration Approvals. [PDF 36KB]
  • News Release

July 13, 2001

  • Application for Extension of the Period During Which Haemacure Corporation May Continue to Seek All Necessary FDA Approvals to Manufacture Fibrin Sealant For Sale in the United States
    • Letter Approving Extension Until July 28, 2002
  • News Release

April 30, 2001

July 18, 2000

  • Letter Approving Request by Trustee to Extend Period Within Which Haemacure Corporation May Seek Necessary FDA Approvals to Manufacture Fibrin Sealant For Sale in the United States through July 28, 2001. [PDF 52K]
  • News Release

May 9, 2000

August 1, 1997

  • Letter Granting Application for Approval of Divestiture of Immuno Fibrin Sealant Assets to Haemacure Corporation.
  • News Release

March 28, 1997

December 19, 1996

 


Last Modified: Friday, August 26, 2011